Blenrep Shows Promise in DREAMM-7 Phase 3 Trial for Relapsed, Refractory Multiple Myeloma
DREAMM-7 was a Phase 3, multicenter, open-label, randomized trial analyzing the efficacy and safety of Blenrep plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously administered at least one prior line of treatment.
GSK announced positive results from an interim analysis of its DREAMM-7 head-to-head Phase 3 trial evaluating belantamab mafodotin (Blenrep) as a second-line treatment for relapsed or refractory multiple myeloma.
Image credit: ibreakstock | stock.adobe.com
According to a company press release, the trial met its primary endpoint of progression-free survival (PFS) and showed that Blenrep when combined with bortezomib plus dexamethasone (BorDex) significantly extended the time to disease progression or death versus daratumumab plus BorDex, an existing standard of care for relapsed/refractory multiple myeloma.1
“Patients with multiple myeloma need treatment options after first relapse that are efficacious, readily accessible and have novel mechanisms of action,” said Hesham Abdullah, SVP, global head, oncology, R&D, GSK, in a press release.1 “We are particularly encouraged by the potential for belantamab mafodotin when combined with BorDex to address high unmet need in relapsed/refractory multiple myeloma, given the head-to-head comparison with the daratumumab-based standard of care regimen.”
Multiple myeloma, a malignant disorder of B cells, is the second most common hematological cancer and is associated with significant morbidity and mortality. Survival rates for the disease have improved over the past few decades because following the launch of promising new targeted treatments and combination therapies; however, most patients with multiple myeloma relapse, including patients who achieved remission.2
Initially, Blenrep had been removed from the market in November of last year following a request from the FDA. According to the International Myeloma Foundation, the request was based upon the previously announced outcome of the DREAMM-3 Phase 3 confirmatory trial, which did not meet the requirements of the FDA Accelerated Approval regulations. Despite the setback, GSK continued its clinical testing of the therapy, hoping to explore its potential further.3,4
Currently, Darzalex, Johnson & Johnson’s (J&J) multiple myeloma treatment, is considered the standard of care treatment in the industry. Based on results of the DREAMM-7 trial, GSK believes Blenrep shows potential as a much stronger treatment, with the study reportedly showring superior results compared to its counterpart.4
DREAMM-7 was a Phase 3, multicenter, open-label, randomized trial analyzing the efficacy and safety of Blenrep plus bortezomib and dexamethasone (BorDex) compared to a combination of daratumumab and BorDex in patients with relapsed/refractory multiple myeloma previously administered at least one prior line of treatment for multiple myeloma, with documented disease progression during or following the most recently administered therapy.
The investigators randomly assigned 494 patients 1:1 ratio to receive either Blenrep plus BorDex or a combination of daratumumab and BorDex. Blenrep was dosed at 2.5 mg/kg intravenously every three weeks.1
GSK stated that its DREAMM clinical development program will evaluate the potential of Blenrep in early lines of treatment and in combination with novel therapies and standard of care treatments. This includes the ongoing head-to-head Phase 3 DREAMM-8 trial evaluating Blenrep in combination with pomalidomide and dexamethasone versus bortezomib in combination with pomalidomide and dexamethasone. More data are expected in the second half of 2024, according to GSK.1
References
1. GSK announces positive results from DREAMM-7 head-to-head phase III trial for Blenrep in relapsed/refractory multiple myeloma. GSK. November 27, 2023. Accessed November 30, 2023. https://www.gsk.com/en-gb/media/press-releases/gsk-announces-positive-results-from-dreamm-7-head-to-head-phase-iii-trial-for-blenrep/
2. Ahmed A, Killeen RB. Relapsed and Refractory Multiple Myeloma. Updated June 8, 2023. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK592405/. Accessed November 30, 2023.
3. Withdrawal of Blenrep from the US Market. International Myeloma Foundation. November 23, 2022. Accessed November 30, 2023. https://www.myeloma.org/news-events/withdrawal-blenrep-us-market
4. GSK's Pulled Myeloma Drug Outperforms J&J's Darzalex in Key Trial. Econo Times. November 28, 2023l. Accessed November 30, 2023. https://www.econotimes.com/GSK-Drug-Pulled-from-Market-Beats-JJs-Multiple-Myeloma-Treatment-in-Phase-3-Test-1666931
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
